Evidence map›Paper›PMID 41618019›Full record

ArticleDiscover oncology2026

PatchSight-ImmuneMap-LifeSpan as a unified AI framework for breast cancer diagnosis, immune profiling and prognostic prediction.

Ahmed Kateb Jumaah Al-Nussairi, Ali B M Ali, Saleem Malik, S Gopal Krishna Patro, Chandrakanta Mahanty, Kasim Sakran Abass, Iman Basheti, Adis Abebaw Dessalegn, Khursheed Muzammil, Sanjay Kumar

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmed Kateb Jumaah Al-NussairiMathematics Department, College of Basic Education, University of Misan, Misan, Iraq.
Ali B M AliAdvanced Technical College, University of Warith Al-Anbiyaa, Karbala, Iraq.
Saleem MalikCSE Department, P A College of Engineering, Mangalore, 574153, India. baronsaleem@gmail.com.
S Gopal Krishna PatroSchool of Engineering, Sreenidhi University, Hyderabad, Telangana, 501301, India.
Chandrakanta MahantyDepartment of Computer Science & Engineering, GITAM Deemed to be University, Visakhapatnam, 530045, India.
Kasim Sakran AbassDepartment of Physiology, Biochemistry, and Pharmacology, College of Veterinary Medicine, University of Kirkuk, Kirkuk, 36001, Iraq.
Iman BashetiPharmaceutical Sciences Department, Faculty of Pharmacy, Jadara University, Irbid, Jordan.
Adis Abebaw DessalegnDepartment of Electrical and Computer Engineering, Faculty of Technology, Debre Markos University, Debre Markos, Ethiopia. addis_abebaw@dmu.edu.et.
Khursheed MuzammilCentral Labs, King Khalid University, AlQura'a, P.O. Box 960, Abha, Saudi Arabia.
Sanjay KumarDepartment of Data Sciences, Galgotias College of Engineering and Technology, Greater Noida, 201310, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer diagnosis, immune cell profile, and survival forecasting are important but usually done separately, limiting clinical interpretation. This work combines histopathological diagnosis, immunological microenvironment analysis, and prognostic modeling into a data-driven pipeline. The proposed system involves three phases: PatchSight Classifier uses an optimized InceptionResNetV2 network with patch-based augmentation and transfer learning to classify benign and malignant breast tissue from the BreakHis dataset; ImmuneMap Detector uses Faster R-CNN on immunohistochemistry images from the LYSTO dataset to detect and quantify tumor-infiltrating lymphocytes; and LifeSpan Prognosticator integrates diagnostic and immune features. The PatchSight Classifier outperformed VGG-16, DenseNet-121, and baseline InceptionResNetV2 models with 98.76% accuracy and 0.98 F1-score at 400× magnification. ResNet-101’s ImmuneMap Detector had 98% detection accuracy and low lymphocyte counting inaccuracy. The LifeSpan Prognosticator identified survival-influencing biomarkers with a C-index above 0.90. This comprehensive computational pathology system improves diagnostic precision, immunological assessment, and survival prediction with interpretable, high-accuracy models. We provide end-to-end decision assistance for early detection, immunological assessment, and personalized breast cancer prognosis.

Indexed as

Breast cancer predictionDeep learningSurvival analysis

Identifiers

PMID41618019
PMCPMC12917075

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.